RxDoctor Payments Data

Steven Tabak, MD

Cardiovascular Disease · Beverly Hills, CANPI 1124090576

Payments from drug & device makers

$5,511in general payments, 2019–2025

Across 76 payments — averaging $72.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • Amgen$662
  • Boston Scientific$226
  • Medtronic$222
  • Novartis$206
  • E.r. Squibb & Sons, L.L.C.$181
  • plus $998 from 17 others

What the payments were for

  • Food & beverage$2,51146%
  • Education$3,00054%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,511 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$255,335
Medicare patients
582
Services billed
2,387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban139$173,783
Repatha SureclickEvolocumab166$165,538
EntrestoSacubitril/Valsartan51$72,986
Praluent PenAlirocumab91$70,623
JardianceEmpagliflozin52$66,301
XareltoRivaroxaban52$63,323
Repatha PushtronexEvolocumab32$29,362
BrilintaTicagrelor14$10,002
VascepaIcosapent Ethyl15$9,570
Rosuvastatin Calcium505$8,795
Ezetimibe291$8,496
Icosapent Ethyl16$6,736
Nebivolol Hcl62$4,254
Atorvastatin Calcium378$3,459
Irbesartan145$2,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$106$173,783139 claims
NovartisEntresto$206$72,98651 claims
Boehringer IngelheimJardiance$22$66,30152 claims
Johnson & JohnsonXarelto$90$63,32352 claims
AstraZenecaBrilinta$75$10,00214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →